Delving into the Latest Updates on Imetelstat with Synapse

Overview

Basic Info

Drug Type

Oligonucleotide

Synonyms

Imetelstat (USAN/INN), Imetelstat sodium, GRN 140719

+ [11]

Target

Telomerase

Action

inhibitors

Mechanism

Telomerase inhibitors

Therapeutic Areas

Hemic and Lymphatic DiseasesOther DiseasesNeoplasms

Active Indication

Transfusion dependent anaemiamyelodysplastic anemiaMyelodysplastic Syndromes+ [14]

Inactive Indication

Advanced Lung Non-Small Cell CarcinomaB-Cell Prolymphocytic LeukemiaCentral Nervous System Neoplasms+ [21]

Originator Organization

Geron Corp.

Active Organization

GCP Service International Ltd & Co KG

Geron Corp.

Inactive Organization

The Children's Oncology Group Foundation, Inc.

License Organization

Geron Corp.

Janssen Biotech, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (06 Jun 2024),

myelodysplastic anemia

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

Sequence Code 29814464

Source: *****

The purpose of this clinical trial is to learn if imetelstat is safe to use in participants with high-risk myeloid malignancies who have received an allogenic hematologic stem cell transplantation (allo-SCT).
Participants will receive imetelstat by intravenous infusion once every 28 days for up to one year.

Start Date01 Feb 2027

Sponsor / Collaborator

University of Wisconsin-Madison

[+1]

NCT07549451

/ Not yet recruitingPhase 2IIT

Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms

To learn if imetelstat can help to control MDS/MPNs.

Start Date08 Oct 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

NCT07320235

/ RecruitingPhase 1IIT

IMetelstat and Azacitidine With or Without Venetoclax GIveN in rElapsed Acute Myeloid Leukemia (IMAGINE Trial)

IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patients with relapsed or refractory AML. The trial will consist of a safety run-in phase (Part A) employing a 3+3 design to monitor dose-limiting toxicities of imetelstat when administered in combination with a fixed dose of azacitidine. Part B will consist of a phase 1b trial employing a BOIN12 design to determine the optimal biological dose of imetelstat, starting at a lower dose level, in combination with azacitidine and venetoclax. Total of up to 36 participants will be accrued over 54 months at Mount Sinai Hospital. Estimated duration of trial is 114 months including recruitment, screening, treatment, and follow-up.

Start Date02 Jan 2026

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

[+1]

100 Clinical Results associated with Imetelstat

Login to view more data

100 Translational Medicine associated with Imetelstat

Login to view more data

100 Patents (Medical) associated with Imetelstat

Login to view more data

154

Literatures (Medical) associated with Imetelstat

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Redox regulation of telomerase and telomeres in cancer: a critical appraisal of exposure, causality and molecular directness

Review

Author: Khorrami, Mehdi ; Masoumi, Mehdi ; Kazemi, Fatemeh ; Tatar, Mohsen ; Khorrami, Mahsan ; Babaei, Shakour

Telomerase reactivation and altered redox metabolism co-occur in most cancers, but the literature joining them is hard to read whole. We separate it into five propositions - redox control of telomerase, telomerase reverse transcriptase (TERT)-dependent control of redox metabolism, oxidative telomere damage, redox-associated alternative lengthening of telomeres, and therapeutic translation - and appraise each along four easily conflated axes: exposure, model, causal test and molecular directness. Much disagreement then reflects design heterogeneity rather than genuine conflict, and one common design is weaker than it appears: millimolar thiol given before a thiol-reactive electrophile cannot separate restored antioxidant capacity from chemical quenching of the compound. Causal strength and molecular directness vary independently. The best-supported redox findings - peroxide-driven Src/Ran-dependent TERT nuclear export, and glutathione depletion with repletion - rest on necessity and rescue but remain pathway-mediated, in transfected or non-cancer systems. The most direct chemistry is biochemical and telomeric: lesion identity and position govern shelterin binding, G-quadruplex folding, repair and telomerase extension, and one acute 8-oxoguanine event causes dysfunction without shortening. We identified no study causally linking a residue-resolved oxidative modification of endogenous TERT to altered assembly, localization or catalysis; imetelstat is the translational counterpart, its randomized efficacy established but redox engagement and telomere pharmacodynamics unmeasured. We set out the measurements that would close both gaps.

01 Oct 2026·European Thyroid Journal

TERT reactivation in thyroid cancer: mechanisms, clinical implications, and therapeutic opportunities

Review

Author: Bullock, Martyn ; Nguyen, Linh T T ; Gild, Matti ; Glover, Anthony

Abstract:

Somatic mutations in the telomerase reverse transcriptase (TERT) promoter are key molecular events in thyroid carcinogenesis and are strongly associated with aggressive clinical behaviour. The c.-124C>T and c.-146C>T hotspot mutations, discovered in 2013, are now recognised as major mechanisms of TERT reactivation and as independent predictors of disease-specific survival, recurrence, and disease refractoriness to radioiodine. TERT can also be reactivated by multiple regulatory layers converging on telomerase upregulation. Beyond telomere maintenance, TERT enhances ribosome biogenesis, cooperates with BRAFV600E-driven transcriptional programmes, and modulates NF-κB-associated inflammatory and stress responses, thereby promoting dedifferentiation and therapy resistance. Clinically, TERT promoter mutations, particularly when co-occurring with BRAFV600E, increase in prevalence from papillary to anaplastic thyroid carcinoma and are associated with an increased risk of radioiodine-refractory disease, supporting their use in risk stratification. However, isolated TERT promoter mutations are more often associated with intermediate risk tumours and comparatively better outcomes, underscoring the importance of molecular context. The recent approval of the telomerase inhibitor imetelstat and the preclinical success of the rRNA transcription inhibitor CX5461 in restoring differentiation and iodine uptake support telomerase- and ribosome-targeted strategies as emerging therapeutic avenues for TERT-driven thyroid cancers.

01 Jun 2026·JCO Oncology Practice

Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents

Review

Author: Madanat, Yazan F. ; Zeidan, Amer M. ; Chung, Stephen S. ; Hoff, Fieke W.

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases that are prognostically stratified into lower-risk (LR-MDS) and higher-risk MDS on the basis of the International Prognostic Scoring System (eg, IPSS, revised IPSS, and molecular IPSS). Anemia is a hallmark of MDS and can lead to worsening of preexisting comorbidities, long-term RBC transfusion dependence, and profound fatigue. Although RBC transfusion support provides rapid relief of anemia-associated symptoms, it also carries a risk of iron overload and alloimmunization, and is associated with a decreased quality of life. Thus, many clinical trials and treatment strategies for LR-MDS focus on RBC transfusion independence (RBC-TI) as a primary end point. In this review, we discuss the updated treatment paradigm for anemia in LR-MDS. Novel insights in the pathogenesis of MDS and results from positive phase III clinical trials in LR-MDS have led to a growing number of therapeutic options (eg, luspatercept and imetelstat). Imetelstat was recently added as a new agent for patients who are refractory/resistant or ineligible for erythropoiesis-stimulating agent treatment on the basis of the randomized phase III IMerge trial, showing that imetelstat led to the primary end point of RBC-TI for ≥8 weeks in 40% of patients compared with 15% in patients receiving placebo. However, future clinical trials are needed to investigate the optimal sequencing of different agents and the potential of improving efficacy using combination of therapeutic strategies in LR-MDS.

194

News (Medical) associated with Imetelstat

28 Oct 2026

·www.fiercepharma.com

Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid

Geron has discontinued a phase 3 trial of its Rytelo in JAK inhibitor-pretreated myelofibrosis after an independent data monitoring committee ruled that the study was unlikely to succeed, just as Novartis is gearing up for a delayed FDA approval bid for its pelabresib. News of the phase 3 IMpactMF trial failure drove down Geron’s stock price by nearly 16% Wednesday to below $1 apiece at close for the first time since a pandemic-led market crash in March 2020. The study was testing Rytelo (imetelstat), a first-in-class telomerase inhibitor, against best available therapy among 327 patients with intermediate-2 or high-risk myelofibrosis who had failed on a JAK inhibitor, such as Incyte and Novartis’ Jakafi. At an interim analysis, the independent data monitoring committee deemed Rytelo unlikely to show a significant overall survival benefit on the trial’s primary endpoint, and Geron followed the panel’s recommendation to end the trial. “Hematologic malignancies are complex diseases, with distinct biological characteristics and treatment challenges across patient populations,” Geron’s R&D chief, Joseph Eid, M.D., said in an Oct. 28 statement. “We remain committed to thoroughly evaluating the data, understanding what we can learn, and sharing insights that may help inform future research and address the significant unmet needs that remain.” Rytelo got its initial FDA approval in 2024 for patients with low- to intermediate-risk myelodysplastic syndromes (MDS) and transfusion-dependent anemia who have failed on, or are ineligible for, erythropoiesis-stimulating agents. MDS is a group of blood cancers in which immature blood cells in the bone marrow fail to mature or become healthy blood cells. For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia and neutropenia are among some serious side effects tied to the drug that require monitoring of patients’ blood cell counts. In IMpactMF, Geron tested a higher, more frequent dose, at 9.4 mg/kg every three weeks. According to Geron’s previous public disclosures, the FDA urged the company to consider adding another dosing arm to the trial to assess a lower dose and/or a more frequent dosing schedule to improve its chance of success. The rationale was that doing so might reduce toxicity with more effective spleen response, one of the trial’s secondary endpoints. However, citing findings from its phase 2 IMbark trial, Geron argued that “testing a lower dose regimen would likely result in a lower median OS” for Rytelo, according to its most recent quarterly filing. “Existing data also suggest that lowering the dose would not result in a clinically meaningful reduction in toxicity, and for these reasons we determined not to add a third dosing arm to the trial design,” the company said. In its Oct. 28 announcement, Geron said the phase 3 trial saw no new safety signals that would “change the known safety profile of imetelstat or require additional safety monitoring.” The company didn’t respond to Fierce’s question on whether it would consider another trial testing a lower dose or whether the trial setback would lead to any job cuts. In response to Fierce’s inquiry, a media aide pointed back to the company’s press release. The company will report third-quarter earnings on Nov. 4. “As we fully analyze the data from the IMpactMF trial, we remain committed to growing Rytelo demand in the U.S. and broadening access to eligible LR-MDS patients outside the U.S.,” Geron’s CEO, Harout Semerjian, said in the release. “We have a growing commercial business, a strong financial foundation, and a clear strategy to pursue innovation to create long-term value and build a leading hematology company.” Toxicity has recently tripped up Novartis’ BET inhibitor candidate, pelabresib, the centerpiece of its $2.9 billion MorphoSys buyout, in myelofibrosis. Citing an imbalance in the rate of malignant transformations into acute myeloid leukemia, Novartis in 2024 had to wait for longer follow-up of the phase 3 Manifest-2 trial in post-JAK inhibitor myelofibrosis to determine pelabresib’s U.S. path. The trial pits pelabresib’s combination with Jakafi against Jakafi alone. The Swiss pharma recently completed filing pelabresib in the EU based on the Manifest-2 results, which the company said “showed deep and durable disease control, with a safety profile comparable to [Jakafi] alone, including numerically fewer deaths and disease progressions in the pelabresib arm,” according to its third-quarter earnings report. Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday. The company is running the phase 3 Manifest-3 trial testing pelabresib-Jakafi in primary myelofibrosis.

Clinical ResultPhase 3Phase 2Accelerated ApprovalDrug Approval

28 Oct 2026

·firstwordpharma.com

Geron's Rytelo expansion bid falters in Phase III myelofibrosis trial

Geron has discontinued a Phase III trial of Rytelo (imetelstat) in myelofibrosis, dealing a blow to efforts to expand the telomerase inhibitor's use beyond lower-risk myelodysplastic syndromes (LR-MDS). Company shares slid more than 15% on the news Wednesday.The setback comes almost a year after Geron trimmed its headcount by roughly a third to focus on commercialising the drug.Rytelo, which competes with Bristol Myers Squibb's erythroid maturation agent Reblozyl (luspatercept), was approved in the US in 2024 to treat transfusion-dependent anaemia in patients with LR-MDS and is Geron's only marketed product.The drug's EU approval is specifically for patients without an isolated deletion 5q cytogenetic abnormality and who have had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.Geron said its decision to stop the Phase III IMpactMF trial followed a recommendation from the independent data monitoring committee concluding the study was unlikely to meet the primary endpoint of overall survival. IMpactMF enrolled 327 patients with intermediate-2 or high-risk myelofibrosis whose disease had relapsed or proved refractory to treatment with a JAK inhibitor. Patients were randomised to receive Rytelo or best available therapy.Geron said no new safety signals were observed that would change the drug's known safety profile or require additional monitoring. Detailed findings will be shared at a future date.TD Cowen analyst Tara Bancroft said the trial outcome was disappointing, but noted that the absence of new safety concerns, despite higher and more frequent dosing than in LR-MDS, supported confidence in Rytelo's ongoing launch.Moreover, while the stoppage removes a potential growth opportunity, Wedbush analyst Robert Driscoll said he doesn't think "this outcome meaningfully alters physician perception of Rytelo in LR-MDS as the compound's approved indication and the anchor of the commercial ⁠story."Rytelo generated $57.5 million in second-quarter sales, compared to $49 million in the corresponding year-ago period, and Geron expects full-year sales of the drug will reach $220 million to $240 million this year."As we fully analyse the data from the IMpactMF trial, we remain committed to growing Rytelo demand in the US and broadening access to eligible LR-MDS patients outside the US," said CEO Harout Semerjian.

Phase 3Drug Approval

28 Oct 2026

·www.biospace.com

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. This decision was based on a recommendation from the independent Data Monitoring Committee (DMC). The independent DMC advised Geron that the trial was unlikely to meet its primary endpoint of overall survival. There were no new safety signals observed in the trial that change the known safety pro imetelstat or require additional safety monitoring. A detailed analysis of the data will be conducted, and study findings will be shared with the scientific community at a future date. “Given the recommendation from the DMC, we believe discontinuing our Phase3 IMpactMF trial at this time is the right course of action. We are deeply grateful to the patients and families, as well as the investigators and clinical teams whose dedication made this research possible,” said Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron. “Hematologic malignancies are complex diseases, with distinct biological characteristics and treatment challenges across patient populations. We remain committed to thoroughly evaluating the data, understanding what we can learn, and sharing insights that may help inform future research and address the significant unmet needs that remain.” IMpactMF evaluated 327 patients with intermediate-2 or high-risk myelofibrosis who were relapsed or refractory to a JAK inhibitor. Patients were randomized 2:1, in an open label, controlled trial of imetelstat designed to evaluate a potential improvement in overall survival compared to best available therapy. Patients in the imetelstat arm received 9.4 mg/kg IV every three weeks. “As we fully analyze the data from the IMpactMF trial, we remain committed to growing RYTELO demand in the U.S. and broadening access to eligible LR-MDS patients outside the U.S.,” said Harout Semerjian, President and Chief Executive Officer of Geron. “We have a growing commercial business, a strong financial foundation, and a clear strategy to pursue innovation to create long-term value and build a leading hematology company.” About Geron Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO ® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit or follow us on LinkedIn . Use of Forward-Looking Statements Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) Geron’s plans to discontinue the Phase 3 IMpactMF trial; (ii) the ongoing analysis of IMpactMF data and the timing and plans for sharing study findings with the scientific community; (iii) the potential for insights from these analyses to inform future research; (iv) Geron’s plans and efforts to grow RYTELO demand in the United States and expand access for eligible patients; (v) Geron’s strategy and ability to create long-term value and build a leading hematology company; and (vi) other statements that are not historical facts. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including risks and uncertainties relating to: (a) the timing, costs and execution of discontinuing IMpactMF; (b) whether further analyses of IMpactMF data yield additional or different findings, including regarding efficacy and safety, and the timing and extent of disclosure of those findings; (c) whether insights from clinical data translate into future research or clinical benefits; (d) the impact of the IMpactMF results and discontinuation on Geron’s development plans, business and financial condition; (e) Geron’s ability to grow RYTELO demand, achieve market acceptance and expand patient access in the United States, including risks relating to competition, coverage and reimbursement; (f) regulatory requirements and actions affecting imetelstat’s development and commercialization; (g) failures or delays in manufacturing or supplying sufficient quantities of RYTELO or clinical trial materials; and (h) Geron’s ability to execute its strategy and maintain sufficient financial resources to support its business. Additional information regarding these and other risks and uncertainties is contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere, including Geron’s annual report on Form 10-K for the year ended December 31, 2025, and subsequent filings and reports. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying them may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. CONTACT: Dawn Schottlandt Senior Vice President, Investor Relations and Corporate Affairs dschottlandt@geron.com

Phase 3Clinical ResultPhase 2

100 Deals associated with Imetelstat

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09629	Imetelstat	L01XX80	DB14909

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Transfusion dependent anaemia	European Union	Geron Corp.	07 Mar 2025
Transfusion dependent anaemia	Iceland	Geron Corp.	07 Mar 2025
Transfusion dependent anaemia	Liechtenstein	Geron Corp.	07 Mar 2025
Transfusion dependent anaemia	Norway	Geron Corp.	07 Mar 2025
myelodysplastic anemia	United States	Geron Corp.	06 Jun 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myelodysplastic Syndromes	NDA/BLA	United States	Geron Corp.	12 Jan 2024
Myelofibrosis	Phase 3	United States	Geron Corp.	12 Apr 2021
Myelofibrosis	Phase 3	Argentina	Geron Corp.	12 Apr 2021
Myelofibrosis	Phase 3	Australia	Geron Corp.	12 Apr 2021
Myelofibrosis	Phase 3	Austria	Geron Corp.	12 Apr 2021
Myelofibrosis	Phase 3	Belgium	Geron Corp.	12 Apr 2021
Myelofibrosis	Phase 3	Brazil	Geron Corp.	12 Apr 2021
Myelofibrosis	Phase 3	Bulgaria	Geron Corp.	12 Apr 2021
Myelofibrosis	Phase 3	Colombia	Geron Corp.	12 Apr 2021
Myelofibrosis	Phase 3	Denmark	Geron Corp.	12 Apr 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2026	Not Applicable	Myelodysplastic Syndromes	468	Imetelstat	tetpvxsukx(ddujwugcml) = zpdhiazreb yxwdjeagwe (htyeuhipbg ) View more	Positive	12 May 2026
				Luspatercept	tetpvxsukx(ddujwugcml) = xaqllrvhgc yxwdjeagwe (htyeuhipbg ) View more
NCT02426086 (IMbark, EHA2026)	Phase 2	Mycosis Fungoides	113	Imetelstat	fvariyttjr(fnfnbtcnhd) = ldeattrpqi yiypslgikk (wwvdvysvky, 25.5 - 36.9)	Positive	12 May 2026
				Best Available Therapy (BAT)	fvariyttjr(fnfnbtcnhd) = nfrppwsajk yiypslgikk (wwvdvysvky, 13.1 - 30.5)
EHA2026	Not Applicable	Myelodysplastic Syndromes	40	Imetelstat	xyzggzabfo(tvllgtilkl) = Among 9 pts with ASXL-1 mutation, 66.7% (6 pts) responded compared to 29% (9/31) WT, p= 0.04 tcgfgmymhw (yykkiwhowf ) View more	Positive	12 May 2026
NCT05583552 (IMpress, CTgov)	Phase 2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes	46	Imetelstat Sodium (Imetelstat Sodium (1 Treatment / Cycle))	xualuuqoeb = kvmtoxwjja ihwaosspwp (krmfjhfnun, cuwxqikdkc - vslvlcdlpq) View more	-	12 May 2026
				Imetelstat Sodium (Imetelstat Sodium (2 Treatments / Cycle))	xualuuqoeb = igtvzhqdae ihwaosspwp (krmfjhfnun, cqbgzyyuuo - ssrxidbwxj) View more
NCT02426086 (IMbark, ASH2025)	Phase 2	Myelofibrosis	43	Imetelstat 8.9 mg/kg	rgctoyjyee(dhvftieion) = zhduyyvdxt waohdtsdtx (dtiiphpilh )	Positive	06 Dec 2025
				Imetelstat 4.4 mg/kg	lzlfmzrbas(hrrhawlpza) = zivhgfrucc bpdjudkcoi (yobzopctxc )
NCT02598661 (IMerge, ASH2025)	Phase 3	Myelodysplastic Syndromes	226	Imetelstat (IME) 7.1 mg/kg	rnktrbifuz(taroujwyhy) = gcawugance vxzcgqhtfl (nluwsnhhpr ) View more	Positive	06 Dec 2025
NCT02598661 (imerge, ASH2025)	Phase 3	Myelodysplastic Syndromes	178	Imetelstat (IME) 7.1 mg/kg	akqrmgjboj(epaguxdxnz) = sjfzsxesst oslwsxkdtc (njixaeczxz, 38.3 - NE) View more	Positive	06 Dec 2025
				Placebo	akqrmgjboj(epaguxdxnz) = opbkgrczls oslwsxkdtc (njixaeczxz, 37.4 - NE) View more
NCT05583552 (IMpress, ASH2025)	Phase 2	Myelodysplastic-Myeloproliferative Diseases	24	Imetelstat sodium	vceizktldt(bgeuzpmypo) = 24 SAEs occurred in 19 patients from August 2024 until 8th May 2025, of which none were deemed related to imetelstat. The most common SAEs were febrile neutropenia (n=6), disease progression/transformation to AML (n=4), sepsis (n=2) and fever (n=2). Overall, 11/24 SAEs resulted in death (n=4 disease progression or AML, n=2 cardiac/cardiorespiratory arrest, n=1 febrile neutropenia, n=1 sepsis, general health alteration and death of unknown reason). 8 of the SAEs resolved without sequelae and 2 remained unresolved. In the first cohort, 30 SAEs occurred in 18 patients, with 3 deemed possibly related to imetelstat (pneumonia [n=2], febrile neutropenia [n=1]). The most common SAEs were disease progression/transformation to AML (n=9), pneumonia (n=3), febrile neutropenia (n=3), and sepsis (n=2). 10/30 SAEs resulted in death. lvafhgmkgi (pdklwzpwit )	Negative	06 Dec 2025
				Imetelstat sodium
ASCO2025	Not Applicable	Myelofibrosis JAK2 mutation \| calreticulin (CALR) mutation	197	Imetelstat 9.7 mg/kg	edrcfnmutf(dllhfdqfpl) = 42% rzgslwppdz (atosrxmawq ) View more	Positive	30 May 2025
NCT02598661 (IMerge, ASCO2025)	Phase 2/3	Myelodysplastic Syndromes ESA \| luspatercept \| lenalidomide ... View more	226	Imetelstat	osmhyomjyn(abpanxmyhv) = zuuvpegnip kubrzxbucd (tcpfavempy ) View more	Positive	30 May 2025